Clinical Trial Update: A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED) [Phase 2]

View source ↗

Summary

A Phase 2 study of SAHA (vorinostat) in relapsed or refractory breast cancer, colorectal cancer, and non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Cancer, Colorectal Cancer | Phase 2 | Status: TERMINATED